T cell therapy has achieved notable success in treating blood cancers. However, it has been largely ineffective against solid tumors. A study demonstrates that a different immunotherapy approach ...
This summer’s IPO by Artiva Biotherapeutics Inc. highlighted early stage efforts with natural killer cells in autoimmune disease, where a handful of companies are advancing programs. The firm raised ...
Natural killer (NK)-cell activation by most pathogens is strictly dependent on the presence of accessory cells, such as monocytes, macrophages or dendritic cells. Direct contact with accessory ...
Natural killer T cells possess innate-like properties that make them uniquely equipped to fight solid tumors. Specifically, they express a T cell receptor that recognizes glycolipid antigens ...